Lorena Diéguez is the leader of the Medical Devices research group at INL. Her research is dedicated to Translational Medical Research in close collaboration with hospitals and focuses on the development of solutions based on microfluidics, biosensors and nanotechnology towards early diagnosis and better understanding of diseases.
She is also very interested in translating her technology from the lab to the clinic and is co-founder and CEO of the spin-off company RUBYnanomed in the field of liquid biopsy. In RUBYnanomed, her role is to bring to market a new tool for patient monitoring and therapy selection in metastatic breast cancer.
Between 2020 and 2021, she was part of the coordination team of INL’s Precise Personalised HealthTech cluster. Also, since 2019 and to date, she is the Chair of the Working Group in Medical Devices at the ETPN (European Technology Platform in Nanomedicine).
She obtained her Bachelors in Physics with Major in Optoelectronics at the University of Santiago de Compostela in 2005, then completed her Masters in Nanotechnology at the University of Barcelona (UB) in 2007 and her PhD in biosensors at the UB, the Institute for Bioengineering of Catalonia and the ETH Zürich. Her postdoc at the University of South Australia (2010-2013) was devoted to the study of rare cells from biological samples using microfluidics. Lorena joined INL in 2014 as Staff Researcher, before being promoted to Research Group Leader in 2018.
She has published over 43 peer-reviewed research articles, reviews, and book chapters. She has participated in 26 national and international research projects, 17 of them as PI, and 6 of them as coordinator. She has also authored 5 patents, and been invited, keynote or plenary speaker in over 30 international conferences. She has also been recipient of several international research and innovation awards.